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1. Introduction  
MicroRNAs (miRNAs) are one class of endogenous non-coding RNA which can repress 
protein translation or cause target mRNA degradation(Bartel 2004). Currently 15,172 entries, 
including 1,048 human miRNAs, are recorded in a major miRNAs database miRbase 
(Release 16: Sept 2010) (Kozomara and Griffiths-Jones 2011). MiRNAs reside reside in 
protein-coding, intronic and intergenic regions throughout the genome. MiRNAs are mainly 
transcribed into long primary miRNAs (pri-miRNAs) by RNA polymerase II(Lee et al. 2004). 
Since mammalian miRNA genes are often clustered along the genome, the pri-miRNA can 
contain one single miRNA gene or multiple clustered miRNA genes. In the nucleus, pri-
miRNAs, which are both capped and polyadenylated, are processed by RNase III enzymes 
Drosha into about 70-nucleotide hairpins called pre-miRNAs(Lee et al. 2002). The 
transporter protein exportin-5 then exports pre-miRNAs to the cytoplasm, where they are 
cleaved by another RNase III Dicer to generate mature miRNA duplexes. One strand of 
miRNA duplex preferentially enters into miRNA-induced silencing complexes (miRISCs) 
and guides the complex to recognize its target genes. Previous studies indicated that this 
target inhibition of miRNAs mainly function via imperfect base pairing with the targeting 
sequences on the 3’ untranslated region(3'UTR) and the first 2–8 bases of a particular mature 
miRNA sequence referred to the ”seed’’ region. MiRNAs play essential regulatory roles in 
diverse biological processes. For example, we recently found that miRNA-153, the 
expression level of which is significantly repressed in glioblastoma (GBM), could inhibit cell 
proliferation and induce apoptosis via targeting B-cell lymphoma 2 (Bcl-2), myeloid cell 
leukemia sequence 1 (Mcl-1) and insulin receptor substrate-2 (Irs-2) in glioblastoma cell 
lines(Xu, Liao, and Wong 2010; Xu et al. 2011).  
In the past few years, computational approaches have played an important role in miRNA 
studies, for example, dozens of prediction tools used for miRNA gene finding and miRNA 
target prediction were developed. These tools have greatly facilitated experimental 
discovery. However, knowledge about the regulation of these essential regulators is at its 
early stage(Schanen and Li 2010; Li et al. 2010). Transcriptional regulations mediated by 
specific transcriptional factors (TFs) have only been intensively studied on a small number 
of miRNAs(Lee et al. 2004; Houbaviy et al. 2005). Importantly, certain “oncogenic miRNAs” 
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and “tumour suppressor miRNAs” are inappropriately expressed in cancers. However, our 
understanding as to the TFs or chromatin modifications responsible for governing the 
expression levels of these essential miRNAs remains limited. 
At the transcriptional level, gene expression is governed by interactions among TFs and cis-
elements such as promoters and enhancers. Chromatin immunoprecipitation (ChIP) 
experiment discovers specific protein-DNA interactions in a given cell type and is regarded 
as a major tool for investigating interactions between TFs and their binding sites. Based on 
the pairing of ChIP with DNA microarray and high-throughput sequencing technologies 
(ChIP-chip and ChIP-seq), genome-wide maps of TF binding sites can now be readily 
produced. Many groups have used ChIP-chip and ChIP-seq assays to globally study direct 
targets of TFs and provided significant insights into gene regulation networks (Farnham 
2009). Together with mRNA-based expression microarrays, vast amounts of data are 
publicly available for analysis by bioinformatics. Indeed, networks of gene expression (or 
systems biology) are gaining popularity to help uncover the physiology regulation 
underneath and interpret the biological meaning behind these networks. 
In principle, one can use the genome-wide binding map of a specific TF (or a chromatic 
modifying factor) to search for its putative target miRNAs, i.e. locate putative binding sites 
inside miRNA regulatory regions (such as promoter or enhancer) according to genomic 
coordinates. In the following section, we present a procedure which uses published ChIP-
chip data to predict candidate miRNAs regulated by a specific TF. Specifically, based on one 
genome-wide estrogen receptor (ER) binding map, we found 59 miRNA regulatory regions 
in which there is at least one ER binding site. Several putative ER-regulated oncogenic and 
tumour suppressor miRNAs were further confirmed in a breast cancer cell model.   
2. Methods  
2.1 Prediction of ER-regulated miRNAs 
Accessing and analyzing the genomic sequence and functional annotations were based on 
the UCSC Genome Browser(Rhead et al. 2010) and Galaxy platform(Goecks, Nekrutenko, 
and Taylor 2010). UCSC Genome Browser is a web tool for convenient displaying and 
accessing the genome sequences, together with rich annotation tracks. Galaxy platform is an 
interactive system that combines existing multiple genome resources via a simple web 
portal. Users can manipulate remote resources and perform flexible operations such as 
intersections, unions, and subtractions. Currently, 718 miRNAs have been annotated in 
human genome (hg18). Their regulatory regions (50 Kb upstream from the pre-miRNAs) 
were collected from UCSC Genome Browser. The original ChIP-chip data were produced by 
Carroll et al. (Carroll et al. 2006). Totally 3,665 estrogens receptor binding regions, which 
were considered with high confidence, were used in this study. Since the original 
coordinates were annotated in hg17, a web-based liftOver utility with default settings was 
used to convert the genomic coordinates to the hg18 version of the human genome 
(http://genome.ucsc.edu/cgi-bin/hgLiftOver). Overlapping regions were searched in 
Galaxy platform. 
2.2 Motif analysis 
The ER binding regions which overlapped with miRNA regulatory sequences were 
download from UCSC Genome Browser and further analyzed by TOUCAN 2, a widely used 
regulatory sequence analysis suite (Aerts et al. 2005). It screened the input sequences against 
a precompiled library of motifs to find the statistically over-represented motifs. TRANSFAC 
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is a database storing eukaryotic transcription factors and the transcription regulating DNA 
sequence elements(Matys et al. 2006). Position weight matrixes (PWMs) were obtained from 
the TRANSFAC 7.0 database. The Eukaryotic Promoter Database (EPD) collected annotated 
eukaryotic RNA polymerase II promoters sequences around the experimentally determined 
transcription start site(Schmid et al. 2006). The human promoter sequence (-499,100 around 
TSS) from EPD were used as background sequences. The 0th order of the Markov model 
with prior 0.1 was chosen to compute both the background sequences and the actual 
sequence frequencies. The p-value and significance value indicate the probability that the 
observed over-representation of the motif is achieved by random selection for a single or 
multiple TFs, respectively.  
2.3 Cells culture, cell counting and qRT-PCR 
MCF-7 cell line was from American Type Culture Collection (Manassas, VA). Cells were 
grown with phenol red-free D-MEM supplemented with 0.5% charcoal stripped FBS for 3 
Days. The estrogen-deprived MCF-7 cells were treated with 10 nM 17ǃ-estradiol (E2, Sigma-
Aldrich Co.) or DMSO as a control. At the indicated time points, cells were rinsed with PBS 
and counted manually under the microscope. Total RNA was collected and extracted with 
Trizol reagent (Invitrogen).   Reverse transcription of mature miRNAs and quantitative real-
time PCR analysis were performed as previously reported(Xu, Liao, and Wong 2010).  
Primers specific for the indicated miRNAs were available upon request. 
3. Results 
3.1 Identifying putative miRNAs regulated by ERs 
Estrogen receptor alpha (ERǂ) and beta (ERǃ) are members of the nuclear receptors super-
family which are ligand-regulated transcription factors. Estrogen (17ǃ-estradiol, E2) is a 
potent ligand for both ERs. ERs either directly interact with cis-regulatory elements of target 
genes by binding to estrogen-response elements (EREs) or indirectly tether to transcription 
factors such as AP1 and SP1 (Ali and Coombes 2002). By transcriptional control of a large 
number of target genes, ERs regulate a wide variety of cellular processes including 
development and differentiation (Deroo and Korach 2006). In particular, ERǂ is thought to 
be involved in the progression of breast cancer. Depending on the status of ERǂ expression, 
breast cancer is classified into ERǂ+ and ERǂ- subtypes. Differential anti-hormone 
treatments are prescribed in conjunction with anti-cancer drugs to manage these breast 
cancer subtypes. Therefore, understanding how ER affects the expressions of oncogenic and 
tumour suppressor miRNAs may assist better development of anti-cancer therapy. 
Carroll et al. previously used ChIP-chip technology to analyze ER binding regions genome-
wide. They found that the majority of ER binding regions are located outside of the classical 
promoter-proximal regions, suggesting distal regulation by ER (Carroll et al. 2006). To 
account for the possible bias when only focusing on promoter-proximal regions, we 
regarded 50 Kb upstream of all known pre-miRNAs as possible regulatory regions. Besides, 
setting a wider candidate region should be beneficial at this exploring step. Totally 59 
miRNA regulatory regions were found that overlapped with 65 Carroll’s ER binding regions 
(Table 1). As shown in Figure 1, there are three representative patterns of ER binding 
regions relative to specific miRNAs. For example, the promoter of hsa-miR-342 contains 
both promoter-proximal and distal ER binding regions, whereas the promoter of hsa-miR-21 
is characterized by two proximal ER binding regions. In contrast, there is only one distal ER 
binding region within the miR-143~145 cluster upstream regulatory region. 
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chromosome chrStart chrEnd miRNA regulatory regions strand 
chr1 149734895 149784895 hsa-mir-554_up_50000_chr1_149734896_f + 
chr1 160528959 160578959 hsa-mir-556_up_50000_chr1_160528960_f + 
chr1 154656845 154706845 hsa-mir-9-1_up_50000_chr1_154656846_r - 
chr1 153381591 153431591 hsa-mir-92b_up_50000_chr1_153381592_f + 
chr10 14468580 14518580 hsa-mir-1265_up_50000_chr10_14468581_f + 
chr10 134911115 134961115 hsa-mir-202_up_50000_chr10_134911116_r - 
chr10 98578511 98628511 hsa-mir-607_up_50000_chr10_98578512_r - 
chr10 29931281 29981281 hsa-mir-938_up_50000_chr10_29931282_r - 
chr11 74723878 74773878 hsa-mir-326_up_50000_chr11_74723879_r - 
chr11 2112015 2162015 hsa-mir-483_up_50000_chr11_2112016_r - 
chr11 64918504 64968504 hsa-mir-612_up_50000_chr11_64918505_f + 
chr12 96431720 96481720 hsa-mir-135a-2_up_50000_chr12_96431721_f + 
chr12 52621788 52671788 hsa-mir-196a-2_up_50000_chr12_52621789_f + 
chr12 63252555 63302555 hsa-mir-548c_up_50000_chr12_63252556_f + 
chr12 12910029 12960029 hsa-mir-614_up_50000_chr12_12910030_f + 
chr12 52664000 52714000 hsa-mir-615_up_50000_chr12_52664001_f + 
chr14 99595744 99645744 hsa-mir-342_up_50000_chr14_99595745_f + 
chr15 60853208 60903208 hsa-mir-190_up_50000_chr15_60853209_f + 
chr15 61950271 62000271 hsa-mir-422a_up_50000_chr15_61950272_r - 
chr15 78921469 78971469 hsa-mir-549_up_50000_chr15_78921470_r - 
chr15 68158861 68208861 hsa-mir-629_up_50000_chr15_68158862_r - 
chr15 73433079 73483079 hsa-mir-631_up_50000_chr15_73433080_r - 
chr16 84332807 84382807 hsa-mir-1910_up_50000_chr16_84332808_r - 
chr16 2211748 2261748 hsa-mir-940_up_50000_chr16_2211749_f + 
chr17 43469612 43519612 hsa-mir-152_up_50000_chr17_43469613_r - 
chr17 55223408 55273408 hsa-mir-21_up_50000_chr17_55223409_f + 
chr17 26876542 26926542 hsa-mir-365-2_up_50000_chr17_26876543_f + 
chr19 10473797 10523797 hsa-mir-1238_up_50000_chr19_10473798_f + 
chr19 58817033 58867033 hsa-mir-1323_up_50000_chr19_58817034_f + 
chr19 10789172 10839172 hsa-mir-199a-1_up_50000_chr19_10789173_r - 
chr19 58811744 58861744 hsa-mir-512-1_up_50000_chr19_58811745_f + 
chr19 58814222 58864222 hsa-mir-512-2_up_50000_chr19_58814223_f + 
chr2 232236267 232286267 hsa-mir-1244_up_50000_chr2_232236268_f + 
chr20 48664729 48714729 hsa-mir-1302-5_up_50000_chr20_48664730_r - 
chr20 48585729 48635729 hsa-mir-645_up_50000_chr20_48585730_f + 
chr20 61971237 62021237 hsa-mir-941-1_up_50000_chr20_61971238_f + 
chr20 61971544 62021544 hsa-mir-941-2_up_50000_chr20_61971545_f + 
chr20 61971656 62021656 hsa-mir-941-3_up_50000_chr20_61971657_f + 
chr22 36570324 36620324 hsa-mir-658_up_50000_chr22_36570325_r - 
chr22 36573727 36623727 hsa-mir-659_up_50000_chr22_36573728_r - 
chr3 187937154 187987154 hsa-mir-1248_up_50000_chr3_187937155_f + 
chr3 129513697 129563697 hsa-mir-1280_up_50000_chr3_129513698_f + 
chr3 50135762 50185762 hsa-mir-566_up_50000_chr3_50135763_f + 
chr3 113264337 113314337 hsa-mir-567_up_50000_chr3_113264338_f + 
chr4 8058008 8108008 hsa-mir-95_up_50000_chr4_8058009_r - 
chr5 167920556 167970556 hsa-mir-103-1_up_50000_chr5_167920557_r - 
chr5 41461490 41511490 hsa-mir-1274a_up_50000_chr5_41461491_f + 
chr5 132791297 132841297 hsa-mir-1289-2_up_50000_chr5_132791298_r - 
chr5 153656858 153706858 hsa-mir-1294_up_50000_chr5_153656859_f + 
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chromosome chrStart chrEnd miRNA regulatory regions strand 
chr5 148738673 148788673 hsa-mir-143_up_50000_chr5_148738674_f + 
chr5 148740401 148790401 hsa-mir-145_up_50000_chr5_148740402_f + 
chr6 166842911 166892911 hsa-mir-1913_up_50000_chr6_166842912_r - 
chr6 135551990 135601990 hsa-mir-548a-2_up_50000_chr6_135551991_f + 
chr6 107288692 107338692 hsa-mir-587_up_50000_chr6_107288693_f + 
chr7 101833307 101883307 hsa-mir-548o_up_50000_chr7_101833308_r - 
chr8 128827389 128877389 hsa-mir-1204_up_50000_chr8_128827390_f + 
chr8 128992060 129042060 hsa-mir-1205_up_50000_chr8_128992061_f + 
chr8 129181543 129231543 hsa-mir-1208_up_50000_chr8_129181544_f + 
chr8 1702803 1752803 hsa-mir-596_up_50000_chr8_1702804_f + 
chr1 154656845 154706845 hsa-mir-9-1_up_50000_chr1_154656846_r - 
chr1 153381591 153431591 hsa-mir-92b_up_50000_chr1_153381592_f + 
chr10 14468580 14518580 hsa-mir-1265_up_50000_chr10_14468581_f + 
chr10 134911115 134961115 hsa-mir-202_up_50000_chr10_134911116_r - 
chr10 98578511 98628511 hsa-mir-607_up_50000_chr10_98578512_r - 
chr10 29931281 29981281 hsa-mir-938_up_50000_chr10_29931282_r - 
chr11 74723878 74773878 hsa-mir-326_up_50000_chr11_74723879_r - 
chr11 2112015 2162015 hsa-mir-483_up_50000_chr11_2112016_r - 
chr11 64918504 64968504 hsa-mir-612_up_50000_chr11_64918505_f + 
chr12 96431720 96481720 hsa-mir-135a-2_up_50000_chr12_96431721_f + 
chr12 52621788 52671788 hsa-mir-196a-2_up_50000_chr12_52621789_f + 
chr12 63252555 63302555 hsa-mir-548c_up_50000_chr12_63252556_f + 
chr12 12910029 12960029 hsa-mir-614_up_50000_chr12_12910030_f + 
chr12 52664000 52714000 hsa-mir-615_up_50000_chr12_52664001_f + 
chr14 99595744 99645744 hsa-mir-342_up_50000_chr14_99595745_f + 
chr15 60853208 60903208 hsa-mir-190_up_50000_chr15_60853209_f + 
chr15 61950271 62000271 hsa-mir-422a_up_50000_chr15_61950272_r - 
chr15 78921469 78971469 hsa-mir-549_up_50000_chr15_78921470_r - 
chr15 68158861 68208861 hsa-mir-629_up_50000_chr15_68158862_r - 
chr15 73433079 73483079 hsa-mir-631_up_50000_chr15_73433080_r - 
chr16 84332807 84382807 hsa-mir-1910_up_50000_chr16_84332808_r - 
chr16 2211748 2261748 hsa-mir-940_up_50000_chr16_2211749_f + 
chr17 43469612 43519612 hsa-mir-152_up_50000_chr17_43469613_r - 
chr17 55223408 55273408 hsa-mir-21_up_50000_chr17_55223409_f + 
chr17 26876542 26926542 hsa-mir-365-2_up_50000_chr17_26876543_f + 
chr19 10473797 10523797 hsa-mir-1238_up_50000_chr19_10473798_f + 
chr19 58817033 58867033 hsa-mir-1323_up_50000_chr19_58817034_f + 
chr19 10789172 10839172 hsa-mir-199a-1_up_50000_chr19_10789173_r - 
chr19 58811744 58861744 hsa-mir-512-1_up_50000_chr19_58811745_f + 
chr19 58814222 58864222 hsa-mir-512-2_up_50000_chr19_58814223_f + 
chr2 232236267 232286267 hsa-mir-1244_up_50000_chr2_232236268_f + 
chr20 48664729 48714729 hsa-mir-1302-5_up_50000_chr20_48664730_r - 
chr20 48585729 48635729 hsa-mir-645_up_50000_chr20_48585730_f + 
chr20 61971237 62021237 hsa-mir-941-1_up_50000_chr20_61971238_f + 
chr20 61971544 62021544 hsa-mir-941-2_up_50000_chr20_61971545_f + 
chr20 61971656 62021656 hsa-mir-941-3_up_50000_chr20_61971657_f + 
chr22 36570324 36620324 hsa-mir-658_up_50000_chr22_36570325_r - 
chr22 36573727 36623727 hsa-mir-659_up_50000_chr22_36573728_r - 
chr3 187937154 187987154 hsa-mir-1248_up_50000_chr3_187937155_f + 
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chromosome chrStart chrEnd miRNA regulatory regions strand 
chr3 129513697 129563697 hsa-mir-1280_up_50000_chr3_129513698_f + 
chr3 50135762 50185762 hsa-mir-566_up_50000_chr3_50135763_f + 
chr3 113264337 113314337 hsa-mir-567_up_50000_chr3_113264338_f + 
chr4 8058008 8108008 hsa-mir-95_up_50000_chr4_8058009_r - 
chr5 167920556 167970556 hsa-mir-103-1_up_50000_chr5_167920557_r - 
chr5 41461490 41511490 hsa-mir-1274a_up_50000_chr5_41461491_f + 
chr5 132791297 132841297 hsa-mir-1289-2_up_50000_chr5_132791298_r - 
chr5 153656858 153706858 hsa-mir-1294_up_50000_chr5_153656859_f + 
chr5 148738673 148788673 hsa-mir-143_up_50000_chr5_148738674_f + 
chr5 148740401 148790401 hsa-mir-145_up_50000_chr5_148740402_f + 
chr6 166842911 166892911 hsa-mir-1913_up_50000_chr6_166842912_r - 
chr6 135551990 135601990 hsa-mir-548a-2_up_50000_chr6_135551991_f + 
chr6 107288692 107338692 hsa-mir-587_up_50000_chr6_107288693_f + 
chr7 101833307 101883307 hsa-mir-548o_up_50000_chr7_101833308_r - 
chr8 128827389 128877389 hsa-mir-1204_up_50000_chr8_128827390_f + 
chr8 128992060 129042060 hsa-mir-1205_up_50000_chr8_128992061_f + 
chr8 129181543 129231543 hsa-mir-1208_up_50000_chr8_129181544_f + 
chr8 1702803 1752803 hsa-mir-596_up_50000_chr8_1702804_f + 
Table 1. miRNA regulatory regions overlapped with ER binding regions. Each miRNA 
regulatory region was annotated with chromosome, start and end position and the strand it 
resides. 
 
Fig. 1. ER binding sites relative to specific miRNAs. The blue boxes represent ER binding 
regions and the black blocks represent upstream 50 Kbp of miRNAs. The pre-miRNAs, miR-
342, miR-21, miR-143~145 were represented by red colour. To note, there are two ER 
binding regions within miR-342 and miR-21 regulatory regions. Correspondingly, miR-143 
and miR-145 share the same ER binding region. 
www.intechopen.com
Genome-Wide Identification of Estrogen Receptor Alpha  
Regulated miRNAs Using Transcription Factor Binding Data 
 
565 
We then used TOUCAN 2 to see whether there are TFs binding sites over-represented in 
these miRNA-related ER-binding regions. The top 10 significant binding motifs are listed in 
Table 2. Not surprisingly, we identified the consensus ERE (AGGTCANNNTGACC) as the 
most common TF binding motif presented in these miRNA regulatory regions bound by ER. 
In addition, we also observed enrichments of activator protein 1(AP-1) and forkhead (FKH) 
motifs among the miRNA-related ER-binding regions. The AP-1 family consists of proteins 
belonging to the JUN, FOS and ATF subfamilies. These subunits can hetero-dimerize and 
bind to their DNA target genes. AP-1 complex modulates a variety of cellular processes in 
response to environmental stimuli. Specially, AP-1 complex is an important regulator in 
tumour development since its target genes are involved in oncogenic transformation, 
tumour suppression, invasive growth and angiogenesis(Wagner 2001; Jochum, Passegue, 
and Wagner 2001). FKH proteins are a super-family of transcription factors that participate 
in regulating the expression of genes involved in cell growth, proliferation and 
differentiation. Many FKH proteins are important to embryonic development, glucose 
homeostasis, tumourigenesis and even vocal learning (Hannenhalli and Kaestner 2009). In 
previous analysis of mRNA targets, these two binding motifs were also shown to enriched 
in ER binding regions, suggesting their role in ER–regulated mRNAs transcription (Carroll 
et al. 2006). Our findings further implied that AP-1 and forkhead family members are 
cooperating transcription factors to regulate ER responsive miRNAs in combinatorial 
fashions.  
In our result, p53 motif is the fourth most significant enriched binding sites in ER binding 
regions. p53 is an essential tumour suppressor because mutations or aberrations in the 
expression of p53 gene were frequently observed in a variety of cancer cell lines and clinical 
tumour samples(Nigro et al. 1989). Liu et al. also found that ERǂ can bind directly to p53 
and repress its target genes (Liu et al. 2006). This important finding has profound 
translational implications because the same group of investigators recently demonstrated 
that (1) Ionizing radiation disrupts the ERǂ-p53 interaction in breast tumours, functionally 
leads to p53 restoration in breast tumours subjected to radiation therapy and elucidates a 
novel mechanism underlying the anti-tumour effect of radiation therapy(Liu et al. 2009); (2) 
The presence of wild-type p53 is an important determinant for responsiveness to anti-
estrogen therapy since anti-estrogens could reactivate p53 by disrupting the ERǂ–p53 
interaction and subsequently p53 activates many tumour suppressor genes(Konduri et al. 
2010). Similar with the situation for mRNA target regulation, we therefore hypothesize that 
ERǂ–p53 interaction may also involve in modulating the transcription of “oncogenic 
miRNAs” and “tumour suppressor miRNAs” although the exact mechanism needs further 
analysis. Except for co-regulator of ERǂ, there is also possible interaction between the 
enriched TFs. For example, cross-talk between glucocorticoid receptor (GR) and AP-1 has 
been well established (Herrlich 2001). In our result, both GR and AP-1 are also enriched in 
the binding region, whether such interactions are involved in miRNAs target regulation 
warrants further investigation.   
In the original analysis of binding sites in mRNA promoters, Carroll et al. found there is a 
strong correlation among ERǂ, Forkhead, Oct, Ap-1 and C/EBP(Carroll et al. 2006). In our 
analysis of miRNA promoter regions, we did not find significant enrichment for Oct and 
C/EBP. But interestingly, several novel TF binding sites (v-Maf, Meis-1, p53, GR-ǂ, RORǂ1, 
Hand1) are over-represented in miRNA-related ER-binding regions. This observation 
perhaps reflect the similar (in the case of common TFs, i.e. ERǂ, FHK and AP-1) and distinct 
modes of ERǂ modulation in miRNA and mRNA gene regulation.   
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TRANSFAC Motif N P-value Sig value TFs 
M00191 33 1.76E-13 10.338 ER-ǂ 
M00035 21 1.52E-7 4.401 v-Maf 
M00419 28 1.22E-6 3.498 Meis-1 
M00272 21 2.32E-5 2.217 P53 
M00192 34 4.13E-5 1.967 GR-ǂ 
M00199 28 5.54E-5 1.84 AP-1 
M00156 16 7.24E-5 1.723 RORǂ1 
M00291 16 8.48E-5 1.655 FOXC1(Forkhead box protein C1) 
M00222 22 1.86E-4 1.313 E47(Hand1) 
M00269 24 2.14E-4 1.254 Xenopus fork head domain factor 3 
Table 2. Top 10 enriched motifs in the miRNA-related ER-binding sites. N: number of times 
TF site appears in the input sequences. Note that TF binding site might appear more than 
once in one sequence. P-value: probability to find even more occurrences than N in the input 
sequences. Sig value: a significance coefficient used to select the most overrepresented 
patterns among the distinct motifs. When analyzing only one TF site, a P-value smaller than 
0.05 could be considered as being over-represented. In case of multiple TF sites, sig-value is 
used to select the significant result. Generally, positive sig values mean significant. 
3.2 Confirmation of ER-regulated miRNA in a breast cancer cell model 
MCF-7 is a well established ERǂ+ cell line that reflects hormone-dependent breast cancer; 
namely, E2 increases MCF-7 cell proliferation. In our hand, the cell number significantly 
increased after four days of treatment with 10 nM E2 compared to DMSO control while a 
late phase increase in cell number was observed starting on day 9 (Figure 2a). Among the 
predicted E2-regulated miRNAs, we randomly selected 8 miRNAs and used qRT-PCR to 
detect the time-dependent changes in their expression levels during cell proliferation. 
Compared to DMSO control, miR-342, miR-21, miR-422a, miR-124, and miR-181c were 
generally found to be up-regulated by E2 treatment; whereas miR-143, miR-145, and miR-
483 were down-regulated (Figure 2b and 2c), suggesting that they are under the respective 
influences of positive and negative EREs.  Intriguingly, the down-regulated miRNAs exhibit 
wave patterns of expression, i.e., significantly suppressed on day 4 with differential levels of 
restoration on day 7 followed by another round of suppression and partial rebound. Other 
than miR-124 which displays a wave pattern of induction, the rest of the E2-induced 
miRNAs show a gradual pattern of induction. The determinants and regulatory networks 
that dictate these patterns of expression await comprehensive investigations. 
Of those up-regulated miRNAs, miR-342 was induced to the highest extent by E2. MiR-342 
is encoded in an intron of the gene EVL and commonly suppressed in human colorectal 
cancer (Grady et al. 2008). Over-expression of miR-342 in the colorectal cancer cell line HT-
29 induced apoptosis, pointing towards a pro-apoptotic tumour suppressor function (Grady 
et al. 2008). On the other hand, miR-342 expression level in breast tumours is more 
complicated with highest level in ER and HER2/neu-positive luminal B tumours but lowest 
level in ER, PR and HER2/neu triple-negative tumours (Lowery et al. 2009). Adding to the 
uncertainty regarding its role, miR-342 is down-regulated in tamoxifen-resistant MCF-7 cells 
(Miller et al. 2008). Consistent with these findings, Cittelly et al. compared miRNA 
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expression profiles between MCF-7/pcDNA (tamoxifen-sensitive) and MCF-7/HER2Δ16 
(tamoxifen-resistant) cells when both cell lines were treated for 24 hr with 100 pM 17-ǃ-
estradiol (E2) and 1μM 4-hydroxytamoxifen (TAM). They found that miR-342 was the most 
dramatically down-regulated miRNA in the tamoxifen resistant MCF-7/HER2Δ16 cells. 
They further proved that other tamoxifen resistant cell lines such as TAMR1 and LCC2, all 
exhibited dramatically suppressed levels of miR-342 whereas another tamoxifen sensitive 
MCF-7/HER2 cell lines also expressed high levels of miR-342, indicating that loss of miR-
342 was a common feature of tamoxifen resistance(Cittelly et al. 2010).  
 
 
Fig. 2. ER binding sites relative to specific miRNAs. (a) The effects of E2 (10 nM) on MCF-7 
cell number over the course of 12 days are shown. (b-c) E2 induces expression of miR-342, 
miR-21, miR-422a, miR-124 and miR-181c; whereas, decreases expression of miR-143, miR-
145 and miR-483 in MCF-7 cells. Cells were treated with E2 (10 nM) for indicated time and 
miRNAs were subjected to qRT–PCR analysis. 
The expression level of miR-21 was previously found to be significantly changed in various 
cancers; especially, it is higher in ERǂ+ than ERǂ– breast tumour (Mattie et al. 2006; Volinia 
et al. 2006). However, inconsistent results were reported regarding the effect of E2 on miR-
21 expression in MCF-7. Wickramasinghe et al. reported that E2 inhibited miR-21 expression 
after 6 hr (Wickramasinghe et al. 2009). In contrast, another group found that miR-21 was 
induced after a 4 hr E2 treatment (Bhat-Nakshatri et al. 2009). In our investigation, we found 
that initially miR-21 was repressed after 4 days on E2. However, miR-21 was up-regulated 
www.intechopen.com
 
Bioinformatics – Trends and Methodologies 
 
568 
by E2 upon long term treatments. MiR-21 is thought to be an oncogenic miRNA (oncomiR) 
and several confirmed endogenous targets such as PDCD-4 and PTEN are important tumor 
suppressers (Asangani et al. 2008; Folini et al. 2010; Meng et al. 2007). Consistent with its 
proposed role as an oncomiR, our results showed that miR-21 expression progressively 
increased from day 7 to day 12 in parallel with the late phase increase in cell number.  
 
 
Fig. 3. ER,AP-1 and p53 binding motifs relative to miR-342,miR-21 and miR-143~145. The 
red, blue and pink boxes represent ER, AP-1 and p53 binding sites respectively. ER_2920 
and ER2921 located in miR-342 upstream region; ER_3188 and ER_3189 located in miR-21 
regulatory region; ER_1259 located in miR-21 upstream region (please referring to Figure 1). 
MiR-143 and miR-145 are clustered miRNAs with their expression levels co-ordinately 
down-regulated in multiple forms of cancer (Akao et al. 2007; Michael et al. 2003; Sevignani 
et al. 2007; Wang et al. 2008). They can function as important tumour suppressers by 
targeting multiple key genes in apoptosis, proliferation, and metastasis signalling pathways 
(Chen et al. 2009; Chiyomaru et al. 2010; Sevignani et al. 2007; Zaman et al. 2010). However, 
whether miR-143 and miR-145 are regulated by E2 in MCF-7 breast cell is unclear. In this 
study, we found that both were repressed by E2 in a long term treatment. Importantly, we 
also observed that ectopic expression of miR-145 repressed MCF-7 cell proliferation (data 
not shown). These observations are consistent with previous studies in other cancers, 
indicating that miR-145 is repressed in cancers compared to the normal control.    
Analyzing the miR-342, miR-21 and miR-143~145 regulatory regions, we found AP-1 
binding motifs in all of them, supporting the role of AP-1 as a basal activator (Figure 3) 
(Wagner 2001). In addition, there are both ER and p53 motifs in the miR-342 upstream 
region, therefore miR-342 may be a dual target of these two TFs and the expression of miR-
342 perhaps depends on both the integrity of estrogen signalling pathway but also the status 
of p53. Estrogen-response elements were detected in both miR-342 and miR-143 promoter 
regions, indicating direct estrogen receptor binding. However, ERE is not present in miR-21 
upstream regulatory region and it is possible that transcriptional activation of miR-21 may 
be mediated via estrogen receptor tethered to AP-1 motifs.  
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Except for miR-342, miR-21, miR-143, and miR-145, little is known for the other miRNAs 
regarding their roles in breast cancer development. Since our analysis has already 
implicated several oncogenic and tumour suppressor miRNAs to be regulated by ER, we 
believe that this strategy can provide promising miRNAs candidates for additional 
functional exploration. 
4. Discussion  
Understanding gene regulation is crucial to elucidating the mechanisms of development, 
differentiation and signaling response. Over the past three decades, advances in 
technologies such as genomic sequencing and expression profiling by microarray have 
paved ways to more thorough investigations into gene regulatory networks. These advances 
also necessitated the development of bioinformatics. Namely, analytical tools and methods 
are continuingly being invented for processing the vast amount of information generated 
and mining the corresponding datasets; hence, new discoveries are observed and novel 
concepts are developed for hypothesis building and testing. Nonetheless, the accumulation 
of datasets sometimes outpaces the development of bioinformatics and a certain amount of 
valuable information is left un-mined. In this chapter, we present a case of utilizing 
developed bioinformatics tools to learn more about gene regulation network based on 
published transcriptional factor binding datasets.  
We used a previous published ER ChIP-chip data to find a set of putative ER-regulated 
miRNAs. This concept and method can be extended to other aspects. Firstly, several ChIP 
based techniques, such as ChIP-PET (paired-end tag), ChIP-DSL (DNA selection and 
ligation), were developed to map TFs binding sites. The genome-wide TF binding sites 
generated from these variations of ChIP-chip techniques could also be used to map the 
miRNAs promoters. Secondly, our methods can be extended to other nuclear hormone 
receptors (NHRs) and TFs providing that corresponding genomic coordinates of TFs 
binding are available. Importantly, the specificity of TF binding sites could be investigated 
by comparing different but related TF binding data. For example, recently by comparison of 
ER and estrogen-related receptor (ERR) binding data in breast cancer cell line MCF-7, 
Deblois et al. showed that ERR and ER display strict binding site specificity while a small 
number of binding sites were shared by both transcriptional factors(Deblois et al. 
2009).Another prominent feature of this versatile procedure lies in its easy application and 
low cost. In recent years, ChIP based techniques are popular assays to study direct targets of 
TFs genome-wide. For example , many NHR binding maps have been published (Deblois 
and Giguere 2008). Surprisingly, few miRNAs regulated by a specific NHR were mined 
from these valuable datasets. The directly targeted miRNAs by a specific NHR or TF can be 
readily discovered through our procedure if the genome-wide binding sites for this TF have 
been produced by others. Thus, it avoids redundant experiments and greatly facilitate rapid 
discovery. 
MiRNAs microarray is a common practice to identify miRNA expression changes upon a 
specific treatment. However, there are some limitations inherited in microarray platform. 
For instance, microarray data is usually mixed with primary, secondary, and even tertiary 
gene expression changes, making it difficult to dissect which TFs are responsible for these 
different levels of regulation. Our procedure directly links the candidate TFs with putative 
target miRNAs through analyzing ChIP-chip and ChIP-seq binding data. Uniquely, our 
analysis also allows investigation into the relationships between mRNAs and miRNAs co-
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ordinately regulated by a specific TF in a given cell type upon a particular treatment, 
providing an entirely new set of information not revealed by mircroarray analysis alone. 
However, it should be noted that not all regulatory regions are included in the original 
design of ChIP-chip platform. Thus, our analysis can only provide a partial picture that is 
dependent on the completeness of ChIP-chip design. As more comprehensive technology 
such as ChIP-seq analysis is used in investigation, the genomic coverage will be significantly 
improved. Besides, TF binding sites may be located outside of the 50 kb upstream regulatory 
region defined in our analysis. Therefore, it is best to complement ChIP data analysis with 
microarray studies to obtain comprehensive information on TFs and miRNAs regulation 
networks. 
5. Conclusion 
Understanding the relationships between transcriptional factors and their target mRNAs is 
greatly facilitated by genome-wide analysis based on the pairing of chromatin 
immunoprecipitation with DNA microarray. However, few miRNAs regulated by 
transcription factors have been mined from these data. Our bioinformatics procedure 
efficiently utilize genome-wide binding data to screen upstream regulatory regions of all 
human miRNAs and hunt for miRNA targets modulated by a specific transcription factor. 
As an example, we predicted 59 putative estrogen-responsive miRNAs based on a published 
genome-wide ER binding dataset. Several ER-regulated miRNAs were further confirmed in 
a breast cancer cell model. Among these, miR-342, miR-21, miR-422a, miR-124, and miR-
181c were generally found to be up-regulated by estrogen treatment; whereas miR-143, miR-
145, and miR-483 were down-regulated. This example demonstrated the power and 
efficiency of this novel analysis method. Furthermore, this example also indicated miRNA 
target of a specific TF can be equally detected from ChIP-chip based binding data, which are 
usually produced for identifying mRNA targets. Integrating our method with routine 
analysis procedure will gain a full picture of gene regulation network by simultaneously 
elucidating the miRNAs and mRNAs targets of a specific TF.    
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